Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices

被引：0

作者：

ARPinho ^{[1
]}

AFortuna ^{[2
,3
]}

AFalco ^{[2
,3
]}

ACSantos ^{[1
,4
]}

RSeia ^{[5
]}

CEstevens ^{[6
]}

FVeiga ^{[1
,4
]}

AJRibeiro ^{[1
,7
]}

机构：

[1] Laboratory of Pharmaceutical Technology,Faculty of Pharmacy,University of Coimbra,Pólo das Ciências da Saúde

[2] Laboratory of Pharmacology,Faculty of Pharmacy,University of Coimbra,Pólo das Ciências da Saúde

[3] CNC-Centre for Neuroscience and Cell Biology,University of Coimbra

[4] REQUIMTE/LAQV,Group of Pharmaceutical Technology,Faculty of Pharmacy,University of Coimbra,Pólo das Ciências da Saúde

[5] Laboratory of Physiology,IBILI,Faculty of Medicine,University of Coimbra,Pólo das Ciênicas da Saúde

[6] Pharmaceutical Development,TECNIMEDE,SAQuinta da Cerca

[7] IS,Instituto de Investiga??o e Inova??o em Saúde,Group Genetics of Cognitive Dysfunction,IBMC-Instituto de Biologia Molecular e Celular

来源：

Journal of Pharmaceutical Analysis | 2019年 / 9卷 / 03期

关键词：

Type; 2; diabetes; Exenatide; Therapeutic drug monitoring; ELISA; HPLC;

D O I：

暂无

中图分类号：

R927 [药物鉴定];

学科分类号：

1007 ;

摘要：

The development of biotechnology-based active pharmaceutical ingredients, such as GLP-1 analogs,brought changes in type 2 diabetes treatment options. For better therapeutic efficiency, these active pharmaceutical ingredients require appropriate administration, without the development of adverse effects or toxicity. Therefore, it is required to develop several quantification methods for GLP-1 analogs products, in order to achieve the therapeutic goals, among which ELISA and HPLC arise. These methods are developed, optimized and validated in order to determine GLP-1 analogs, not only in final formulation of the active pharmaceutical ingredient, but also during preclinical and clinical trials assessment.This review highlights the role of ELISA and HPLC methods that have been used during the assessment for GLP-1 analogs, especially for exenatide.

引用

页码：143 / 155

页数：13

共 66 条

[1]

Tf ligand-receptor-mediated exenatide-Zn＜sup＞2+＜/sup＞ complex oral-delivery system for penetration enhancement of exenatide[J] . Liping Zhang,Yanan Shi,Yina Song,Dongyu Duan,Xuemei Zhang,Kaoxiang Sun,Youxin Li.Journal of Drug Targeting . 2018 (10)

[2]

Recent developments and applications of different sorbents for SPE and SPME from biological samples[J] . Beshare Hashemi,Parvin Zohrabi,Mojtaba Shamsipur.Talanta . 2018

[3]

The use of low molecular weight protamine to enhance oral absorption of exenatide[J] . Liping Zhang,Yanan Shi,Yina Song,Xinfeng Sun,Xuemei Zhang,Kaoxiang Sun,Youxin Li.International Journal of Pharmaceutics . 2018 (1-2)

[4]

A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides[J] . Simone Esposito,Maria Lucia de Leonibus,Raffaele Ingenito,Elisabetta Bianchi,Laura Orsatti,Edith Monteagudo.Journal of Pharmaceutical and Biomedical Analysis . 2018

[5]

A review of analytical procedures for the simultaneous determination of medically important veterinary antibiotics in environmental water: Sample preparation, liquid chromatography, and mass spectrometry[J] . Chansik Kim,Hong-Duck Ryu,Eu Gene Chung,Yongseok Kim,Jae-kwan Lee.Journal of Environmental Management . 2018

[6]

Effects of the multilayer structures on Exenatide release and bioactivityinmicrosphere/thermosensitive hydrogel system[J] . Puxiu Wang,Yue li,Mingyan Jiang.Colloids and Surfaces B: Biointerfaces . 2018

[7]

In vivo evaluation of an oral self-emulsifying drug delivery system （SEDDS） for exenatide[J] . Claudia Menzel,Thomas Holzeisen,Flavia Laffleur,Sergey Zaichik,Muthanna Abdulkarim,Mark Gumbleton,Andreas Bernkop-Schnürch.Journal of Controlled Release . 2018

[8]

Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach[J] . Shivani Srivastava,Priya Shree,Yamini Bhusan Tripathi.Journal of Diabetes ＆ Metabolic Disorders . 2017 (1)

[9]

Purification, identification and molecular mechanism of two dipeptidyl peptidase IV （DPP-IV） inhibitory peptides from Antarctic krill （ Euphausia superba ） protein hydrolysate[J] . Wei Ji,Chaohua Zhang,Hongwu Ji.Journal of Chromatography B . 2017

[10]

Insulin glargine and its two active metabolites: A sensitive （16＜ce:hsp sp="0.25"/＞pM） and robust simultaneous hybrid assay coupling immunoaffinity purification with LC–MS/MS to support biosimilar clinical studies[J] . Yang Xu,Li Sun,Melanie Anderson,Philippe Bélanger,Vincent Trinh,Patricia Lavallée,Bhavna Kantesaria,Marie-Josée Marcoux,Sheila Breidinger,Kevin P. Bateman,Dina Goykhman,Eric J. Woolf.Journal of Chromatography B . 2017

← 1 2 3 4 5 6 7 →